Safety and immunogenicity of a recombinant receptor‐binding domain‐based protein subunit vaccine (Noora vaccine™) against COVID‐19 in adults: A randomized, double‐blind, placebo‐controlled, Phase 1 trial-Reference-Cited by-同舟云学术

Safety and immunogenicity of a recombinant receptor‐binding domain‐based protein subunit vaccine (Noora vaccine™) against COVID‐19 in adults: A randomized, double‐blind, placebo‐controlled, Phase 1 trial

Published:2022-09-13 Issue:2 Volume:95 Page:
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:Journal of Medical Virology

Author:

Salimian Jafar¹²^ORCID,Ahmadi Ali³^ORCID,Amani Jafar¹^ORCID,Olad Gholamreza⁴^ORCID,Halabian Raheleh¹^ORCID,Saffaei Ali⁵⁶⁷^ORCID,Arabfard Masoud²^ORCID,Nasiri Mojtaba⁸^ORCID,Nazarian Shahram⁹,Abolghasemi Hassan¹^ORCID,Alishiri Gholamhossein²^ORCID

Affiliation:

1. Applied Microbiology Research Center, Systems Biology and Poisonings Institute Baqiyatallah University of Medical Sciences Tehran Iran

2. Chemical Injuries Research Center Baqiyatallah University of Medical Sciences Tehran Iran

3. Molecular Biology Research Center, Systems Biology and Poisonings Institute Baqiyatallah University of Medical Sciences Tehran Iran

4. Applied Biotechnology Research Center Baqiyatallah University of Medical Sciences Tehran Iran

5. Department of Clinical Pharmacy, School of Pharmacy Shahid Beheshti University of Medical Sciences Tehran Iran

6. Student Research Committee Shahid Beheshti University of Medical Sciences Tehran Iran

7. Skull Base Research Center, Loghman Hakim Hospital Shahid Beheshti University of Medical Sciences Tehran Iran

8. Clinical Trial Center Tehran University of Medical Sciences Tehran Iran

9. Department of Biology, Faculty of Science Imam Hossein University Tehran Iran

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.28097

Reference40 articles.

1. The 2019 novel coronavirus disease (COVID-19) pandemic: A review of the current evidence

2. Lessons from COVID-19 mortality data across countries

3. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study

4. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial

5. Tocilizumab administration in a refractory case of COVID-19

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up;International Immunopharmacology;2024-06

2. Comparative Immunogenicity and Neutralization Potency of Four Approved COVID-19 Vaccines in BALB/c Mice;IRAN J IMMUNOL;2024

3. Retraction: “Safety and immunogenicity of a recombinant receptor‐binding domain‐based protein subunit vaccine (Noora vaccine™) against COVID‐19 in adults: A randomized, double‐blind, placebo‐controlled, Phase 1 trial”;Journal of Medical Virology;2024-03

4. Protein subunit vaccines: Promising frontiers against COVID-19;Journal of Controlled Release;2024-02

5. Immunogenicity of different nanoparticle adjuvants containing recombinant RBD coronavirus antigen in animal model;Biotechnology and Applied Biochemistry;2023-11-30